Supplemental	
Notice of Allowability	,

Application No.	Applicant(s)		
10/000,113	SCHOENHARD, GRANT L.		
Examiner	Art Unit		
Vickie Kim	1618		

Notice of Allowability	Examiner	Art Unit			
	Vickie Kim	1618			
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.					
1. 🖾 This communication is respónsive to <u>telephonic interview o</u>	<u>n 5/17/05</u> .				
2. The allowed claim(s) is/are <u>363-369,373,374 and 376</u> .					
3. \boxtimes The drawings filed on <u>30 October 2001</u> are accepted by the	e Examiner.	•			
4. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some* c) None of the: 1. Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No 3. Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)). * Certified copies not received: Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.					
5. A SUBSTITUTE OATH OR DECLARATION must be submit INFORMAL PATENT APPLICATION (PTO-152) which give			IOTICE OF		
 6. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted. (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached 1) ☐ hereto or 2) ☐ to Paper No./Mail Date (b) ☐ including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No./Mail Date Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the header according to 37 CFR 1.121(d). 7. ☐ DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL. 					
Attachment(s) 1. Notice of References Cited (PTO-892) 2. Notice of Draftperson's Patent Drawing Review (PTO-948) 3. Information Disclosure Statements (PTO-1449 or PTO/SB/0 Paper No./Mail Date 4. Examiner's Comment Regarding Requirement for Deposit of Biological Material	5. Notice of Informal P. 6. Interview Summary Paper No./Mail Dat 7. Examiner's Amendn 8. Examiner's Stateme 9. Other	(PTO-413), e nent/Comment			

U.S. Patent and Trademark Office PTOL-37 (Rev. 1-04) Application/Control Number: 10/000,113 Page 2

Art Unit: 1618

Supplemental EXAMINER'S AMENDMENT

1. A supplemental examiner's amendment to the record appears below. This instant amendment is issued to correct typographical errors found in examiner's amendment mailed on 5/6/05 and supercedes all the previous office action. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Mr. Harlin, Michael on 5/17/05.

- 2. The application has been amended as follows:
 - a. Cancel claims 1-362, 370-371, 375, and 377-393.
 - b. Rewrite the claim 364 as following:
 - --- 364.(Currently amended) A composition comprising
 - (a) a non-opioid CNS-active agent, wherein the said non-opioid CNS agent is selected from the group consisting of diazepam, lithium, triazolam, and zolpidem, and
 - (b) an ABC drug transporter protein-inhibiting amount of an opioid inhibitor of an ABC drug transporter, wherein the amount is in the range of from 3ng/kg to 3000ng/kg. ---
 - c. In claim 363, line 1, replace [362] with -- 367 -- right after "claim".

Application/Control Number: 10/000,113 Page 3

Art Unit: 1618

d. In claim 373, line 2, insert -- wherein the said non-opioid CNS agent is selected from the group consisting of diazepam, lithium, triazolam, and zolpidem, -- right after "agent".

Conclusion

- 1. All the pending claims 363-369 and 373-374, 376 are allowed.
- 2. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Vickie Kim whose telephone number is 571-272-0579. The examiner can normally be reached on Tuesday-Friday.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Chris Low be reached on 571-272-0953. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

PRIMARY EXAMINER

y/dk/e Kim May 17 2005 Art unit 1618